Literature DB >> 25593102

Spinocerebellar ataxia 36 (SCA36): «Costa da Morte ataxia».

M Arias1, M García-Murias2, M J Sobrido2.   

Abstract

INTRODUCTION-
OBJECTIVE: To describe the history of the discovery of SCA36 and review knowledge of this entity, which is currently the most prevalent hereditary ataxia in Galicia (Spain) owing to a founder effect. DEVELOPMENT: SCA36 is an autosomal dominant hereditary ataxia with late onset and slow progression. It presents with cerebellar ataxia, sensorineural hearing loss, and discrete motor neuron impairment (tongue atrophy with denervation, discrete pyramidal signs). SCA36 was first described in Japan (Asida River ataxia) and in Galicia(Costa da Morte ataxia). The condition is caused by a genetic mutation (intronic hexanucleotide repeat expansion) in the NOP56 gene on the short arm of chromosome 20 (20p13). Magnetic resonance image study initially shows cerebellar vermian atrophy that subsequently extends to the rest of the cerebellum and finally to the pontomedullary region of the brainstem without producing white matter lesions. Peripheral nerve conduction velocities are normal, and sensorimotor evoked potential studies show delayed conduction of stimuli to lower limbs. In patients with hearing loss, audiometric studies show a drop of >40dB in frequencies exceeding 2,500Hz. Auditory evoked potential studies may also show lack of waves I and II.
CONCLUSIONS: Costa da Morte ataxia or SCA36 is the most prevalent SCA in the Spanish region of Galicia. Given the region's history of high rates of emigration, new cases may be diagnosed in numerous countries, especially in Latin America. Genetic studies are now available to patients and asymptomatic carriers. Since many people are at risk for this disease, we will continue our investigations aimed at elucidating the underlying pathogenic molecular mechanisms and discovering effective treatment.
Copyright © 2014 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Ataxia da Costa da Morte; Ataxia espinocerebelosa tipo 36; Costa da Morte ataxia; Expansión de hexanucleótido; Hereditary ataxias; Heredoataxias; Hexanucleotide expansion; NOP56; Spinocerebellar ataxia type 36

Mesh:

Year:  2015        PMID: 25593102     DOI: 10.1016/j.nrl.2014.11.005

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  4 in total

Review 1.  Deafness and Vestibulopathy in Cerebellar Diseases: a Practical Approach.

Authors:  Orlando G Barsottini; José Luiz Pedroso; Carlos Roberto Martins; Marcondes Cavalcante França; Pedro Mangabeira Albernaz
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

2.  Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36.

Authors:  Zachary T McEachin; Tania F Gendron; Nisha Raj; María García-Murias; Anwesha Banerjee; Ryan H Purcell; Patricia J Ward; Tiffany W Todd; Megan E Merritt-Garza; Karen Jansen-West; Chadwick M Hales; Tania García-Sobrino; Beatriz Quintáns; Christopher J Holler; Georgia Taylor; Beatriz San Millán; Susana Teijeira; Toru Yamashita; Ryuichi Ohkubo; Nicholas M Boulis; Chongchong Xu; Zhexing Wen; Nathalie Streichenberger; Brent L Fogel; Thomas Kukar; Koji Abe; Dennis W Dickson; Manuel Arias; Jonathan D Glass; Jie Jiang; Malú G Tansey; María-Jesús Sobrido; Leonard Petrucelli; Wilfried Rossoll; Gary J Bassell
Journal:  Neuron       Date:  2020-05-05       Impact factor: 17.173

3.  Patterns of genetic differentiation and the footprints of historical migrations in the Iberian Peninsula.

Authors:  Clare Bycroft; Ceres Fernandez-Rozadilla; Clara Ruiz-Ponte; Inés Quintela; Ángel Carracedo; Peter Donnelly; Simon Myers
Journal:  Nat Commun       Date:  2019-02-01       Impact factor: 14.919

4.  A nop56 Zebrafish Loss-of-Function Model Exhibits a Severe Neurodegenerative Phenotype.

Authors:  Ana Quelle-Regaldie; Mónica Folgueira; Julián Yáñez; Daniel Sobrido-Cameán; Anabel Alba-González; Antón Barreiro-Iglesias; María-Jesús Sobrido; Laura Sánchez
Journal:  Biomedicines       Date:  2022-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.